



US006746671B2

(12) **United States Patent**  
Steidler et al.

(10) **Patent No.:** **US 6,746,671 B2**  
(45) **Date of Patent:** **Jun. 8, 2004**

(54) **USE OF A CYTOKINE-PRODUCING LACTOCOCCUS STRAIN TO TREAT COLITIS**

(75) Inventors: **Lothar Steidler**, Lokeren (BE); **Erik R. Remaut**, Vinderhouse (BE); **Walter Fiers**, Destelbergen (BE)

(73) Assignee: **Vlaams Interuniversitair Instituut voor Biotechnologie VZW**, Zwijnaarde (BE)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/838,718**

(22) Filed: **Apr. 19, 2001**

(65) **Prior Publication Data**

US 2002/0019043 A1 Feb. 14, 2002

**Related U.S. Application Data**

(63) Continuation of application No. PCT/EP99/07800, filed on Oct. 6, 1999.

(30) **Foreign Application Priority Data**

Oct. 20, 1998 (EP) ..... 98203529

(51) **Int. Cl.**<sup>7</sup> ..... **A01N 63/00**; A61K 48/00

(52) **U.S. Cl.** ..... **424/93.2**; 435/252.3; 435/471; 435/243; 424/93.4

(58) **Field of Search** ..... 424/93.2, 93.4, 424/184.1; 435/243, 471, 252.1, 252.3, 252.31, 461; 514/44

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

6,262,119 B1 \* 7/2001 Ferrante et al. .... 514/560

**FOREIGN PATENT DOCUMENTS**

WO WO 96/11277 \* 4/1996  
WO WO 97/14806 4/1997  
WO WO 00/23471 4/2000

**OTHER PUBLICATIONS**

Herfarth et al., Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers, 1996, GUT, vol. 39, pp. 836–845.\*  
Barbara et al., interleukin 10 gene transfer prevents experimental colitis in rats, 2000, GUT, vol. 46, pp. 344–349.\*

Bellini, et al., Production processes of recombinant IL-1beta from bacillus subtilis: comparison between intracellular and exocellular expression, 1991, Journal of Biotechnology, vol. 18, pp. 177–192.\*

Kuby, Cytokine receptors, 1994, Immunology, pp. 304–306.\*

Pouwels et al., Genetics of lactobacilli: plasmids and gene expression, 1993, Antonie Van Leeuwenhoek, vol. 64, pp: 85–107.\*

Targan et al., Clarifying the causes of Croh’s, 1995, Nature Medicine, vol. 1, pp. 1241–1243.\*

Papadakis et al., Role of cytokine in the pathogenesis of inflammatory bowel disease, 2000, Annu. Rev. Med., vol. 51, pp. 289–298.\*

Korelitz et al., Immunosuppressive therapy of inflammatory bowel disease: A historical perspective.\*

Leach et al., The role of IL-10 in inflammatory bowel disease: “Of mice and men”, 1999, Toxicologic Pathology, pp. 123–133.\*

Page et al., Innovations in oral gene delivery: challenges and potentials, 2001, DDT, vol. 6, pp. 92–101.\*

Verma et al., Gene therapy—promises; problems and prospects, 1997, Nature, vol. 389, pp. 239–242.\*

McGluskie et al., Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates, 1999, Molecular Medicine, vol. 5, pp. 287–300.\*

Anderson, Human gene therapy, 1998, Nature, vol. 392, pp.\*  
Merriam–Webster’s Collegiate Dictionary, Tenth Edition, Springfield, Massachusetts, USA, 2001, p. 922.\*

Steidler et al., “Mucosal Delivery of Murine Interleukin-2 (IL-2) and IL-6 by Recombinant Strains of Lactococcus lactis Coexpressing Antigen and Cytokine”, *Infection and Immunity*, vol. 66, No. 7, pp. 3183–3189, Jul. 1998.

Steidler et al., “Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10”, *Science*, vol. 289, pp. 1352–1355, Aug. 25, 2000.

\* cited by examiner

*Primary Examiner*—Scott D. Priebe

*Assistant Examiner*—Brian Whiteman

(74) *Attorney, Agent, or Firm*—TraskBritt

(57)

**ABSTRACT**

An administration strategy for the delivery at the intestinal mucosa of cytokines or cytokine antagonists, preferably of acid sensitive anti-inflammatory agents, for example, IL10 and/or soluble TNF receptor via the oral route. Preferably, inoculation occurs along with a suspension of recombinant *Lactococcus lactis* cells, which had been engineered to produce the respective proteins.

**14 Claims, 11 Drawing Sheets**